Does the media prefer KYMR or ONC?

In the previous week, Kymera Therapeutics had 30 more articles in the media than BeOne Medicines. MarketBeat recorded 43 mentions for Kymera Therapeutics and 13 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.18 beat Kymera Therapeutics' score of 0.10 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 12 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KYMR or MRNA?

In the previous week, Kymera Therapeutics had 20 more articles in the media than Moderna. MarketBeat recorded 43 mentions for Kymera Therapeutics and 23 mentions for Moderna. Moderna's average media sentiment score of 0.50 beat Kymera Therapeutics' score of 0.10 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 12 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 9 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BNTX or KYMR?

In the previous week, Kymera Therapeutics had 39 more articles in the media than BioNTech. MarketBeat recorded 43 mentions for Kymera Therapeutics and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.37 beat Kymera Therapeutics' score of 0.10 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 12 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KYMR or ROIV?

In the previous week, Kymera Therapeutics had 34 more articles in the media than Roivant Sciences. MarketBeat recorded 43 mentions for Kymera Therapeutics and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.15 beat Kymera Therapeutics' score of 0.10 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 12 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INSM or KYMR more profitable?

Insmed has a net margin of -144.44% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Kymera Therapeutics -611.94% -24.71% -22.05%

Does the media prefer INSM or KYMR?

In the previous week, Kymera Therapeutics had 23 more articles in the media than Insmed. MarketBeat recorded 43 mentions for Kymera Therapeutics and 20 mentions for Insmed. Insmed's average media sentiment score of 0.96 beat Kymera Therapeutics' score of 0.10 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 12 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 12 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kymera Therapeutics (KYMR) Competitors

$108.12 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$108.20 +0.08 (+0.07%)

As of 05:23 AM Eastern

Compare

KYMR vs. ONC, MRNA, BNTX, ROIV, and INSM

Should you buy Kymera Therapeutics stock or one of its competitors? MarketBeat compares Kymera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kymera Therapeutics include BeOne Medicines (ONC), Moderna (MRNA), BioNTech (BNTX), Roivant Sciences (ROIV), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Kymera Therapeutics compare to BeOne Medicines?

Kymera Therapeutics (NASDAQ:KYMR) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Kymera Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Kymera Therapeutics currently has a consensus price target of $118.18, suggesting a potential upside of 9.31%. BeOne Medicines has a consensus price target of $390.00, suggesting a potential upside of 39.34%. Given BeOne Medicines' higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

BeOne Medicines has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	226.83	-$311.35M	-$3.57	N/A
BeOne Medicines	$5.34B	5.75	$286.93M	$4.47	62.62

48.6% of BeOne Medicines shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Kymera Therapeutics had 30 more articles in the media than BeOne Medicines. MarketBeat recorded 43 mentions for Kymera Therapeutics and 13 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.18 beat Kymera Therapeutics' score of 0.10 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	12 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a net margin of 8.94% compared to Kymera Therapeutics' net margin of -611.94%. BeOne Medicines' return on equity of 12.06% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
BeOne Medicines	8.94%	12.06%	6.69%

Summary

BeOne Medicines beats Kymera Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to Moderna?

Kymera Therapeutics (NASDAQ:KYMR) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Kymera Therapeutics had 20 more articles in the media than Moderna. MarketBeat recorded 43 mentions for Kymera Therapeutics and 23 mentions for Moderna. Moderna's average media sentiment score of 0.50 beat Kymera Therapeutics' score of 0.10 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	12 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	9 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna has a net margin of -143.55% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Moderna	-143.55%	-26.64%	-19.32%

Kymera Therapeutics has higher earnings, but lower revenue than Moderna. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	226.83	-$311.35M	-$3.57	N/A
Moderna	$1.94B	13.73	-$2.82B	-$8.15	N/A

Kymera Therapeutics currently has a consensus target price of $118.18, suggesting a potential upside of 9.31%. Moderna has a consensus target price of $37.13, suggesting a potential downside of 44.80%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Kymera Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

75.3% of Moderna shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Summary

Kymera Therapeutics beats Moderna on 11 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, Kymera Therapeutics had 39 more articles in the media than BioNTech. MarketBeat recorded 43 mentions for Kymera Therapeutics and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.37 beat Kymera Therapeutics' score of 0.10 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	12 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioNTech has a net margin of -44.39% compared to Kymera Therapeutics' net margin of -611.94%. BioNTech's return on equity of -5.30% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

BioNTech currently has a consensus target price of $129.56, indicating a potential upside of 42.03%. Kymera Therapeutics has a consensus target price of $118.18, indicating a potential upside of 9.31%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kymera Therapeutics has lower revenue, but higher earnings than BioNTech. Kymera Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.11	-$1.29B	-$5.88	N/A
Kymera Therapeutics	$39.21M	226.83	-$311.35M	-$3.57	N/A

BioNTech has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market.

Summary

BioNTech beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to Roivant Sciences?

Kymera Therapeutics (NASDAQ:KYMR) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

In the previous week, Kymera Therapeutics had 34 more articles in the media than Roivant Sciences. MarketBeat recorded 43 mentions for Kymera Therapeutics and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.15 beat Kymera Therapeutics' score of 0.10 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	12 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.8% of Roivant Sciences shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Kymera Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Kymera Therapeutics presently has a consensus price target of $118.18, indicating a potential upside of 9.31%. Roivant Sciences has a consensus price target of $33.59, indicating a potential downside of 1.41%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Kymera Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Kymera Therapeutics has a net margin of -611.94% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Roivant Sciences has lower revenue, but higher earnings than Kymera Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	226.83	-$311.35M	-$3.57	N/A
Roivant Sciences	$8.26M	2,966.77	-$299.77M	-$0.60	N/A

Summary

Kymera Therapeutics beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Insmed has a net margin of -144.44% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Kymera Therapeutics has lower revenue, but higher earnings than Insmed. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.95	-$1.28B	-$5.75	N/A
Kymera Therapeutics	$39.21M	226.83	-$311.35M	-$3.57	N/A

Insmed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market.

Insmed presently has a consensus target price of $211.86, suggesting a potential upside of 104.94%. Kymera Therapeutics has a consensus target price of $118.18, suggesting a potential upside of 9.31%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Insmed is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Kymera Therapeutics had 23 more articles in the media than Insmed. MarketBeat recorded 43 mentions for Kymera Therapeutics and 20 mentions for Insmed. Insmed's average media sentiment score of 0.96 beat Kymera Therapeutics' score of 0.10 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	12 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Insmed and Kymera Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Kymera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYMR vs. The Competition

Export

Metric	Kymera Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.89B	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-30.29	21.75	25.89	24.17
Price / Sales	226.83	334.18	546.41	101.77
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	5.57	8.31	10.79	6.38
Net Income	-$311.35M	$23.92M	$3.58B	$337.00M
7 Day Performance	8.72%	1.93%	1.97%	-0.20%
1 Month Performance	32.79%	-0.41%	-0.24%	-1.40%
1 Year Performance	145.06%	65.22%	34.40%	27.76%

Kymera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYMR Kymera Therapeutics	1.8755 of 5 stars	$108.12 flat	$118.18 +9.3%	+145.1%	$8.89B	$39.21M	N/A	170	Trending News Analyst Forecast Insider Trade Gap Up High Trading Volume
ONC BeOne Medicines	4.779 of 5 stars	$274.60 +1.0%	$390.00 +42.0%	+16.0%	$30.16B	$5.34B	61.50	12,000	Analyst Upgrade
MRNA Moderna	1.1115 of 5 stars	$63.03 +6.2%	$36.60 -41.9%	+147.7%	$24.90B	$1.94B	N/A	4,700	Trending News Analyst Forecast Gap Down
BNTX BioNTech	4.1414 of 5 stars	$91.36 +1.3%	$129.56 +41.8%	-14.5%	$23.11B	$3.25B	N/A	7,807	Positive News Gap Down
ROIV Roivant Sciences	2.0274 of 5 stars	$31.32 +0.2%	$33.59 +7.2%	+199.1%	$22.53B	$8.26M	N/A	860	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYMR) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kymera Therapeutics (KYMR) Competitors

KYMR vs. ONC, MRNA, BNTX, ROIV, and INSM

How does Kymera Therapeutics compare to BeOne Medicines?

Summary

How does Kymera Therapeutics compare to Moderna?

Summary

How does Kymera Therapeutics compare to BioNTech?

Summary

How does Kymera Therapeutics compare to Roivant Sciences?

Summary

How does Kymera Therapeutics compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kymera Therapeutics (KYMR) Competitors

KYMR vs. ONC, MRNA, BNTX, ROIV, and INSM

How does Kymera Therapeutics compare to BeOne Medicines?

Which has more risk and volatility, KYMR or ONC?

Do analysts rate KYMR or ONC?

Which has preferable valuation and earnings, KYMR or ONC?

Do institutionals and insiders have more ownership in KYMR or ONC?

Does the media prefer KYMR or ONC?

Is KYMR or ONC more profitable?

Summary

How does Kymera Therapeutics compare to Moderna?

Does the media prefer KYMR or MRNA?

Is KYMR or MRNA more profitable?

Which has better earnings & valuation, KYMR or MRNA?

Do analysts prefer KYMR or MRNA?

Do insiders and institutionals have more ownership in KYMR or MRNA?

Which has more risk & volatility, KYMR or MRNA?

Summary

How does Kymera Therapeutics compare to BioNTech?

Does the media refer more to BNTX or KYMR?

Is BNTX or KYMR more profitable?

Do analysts recommend BNTX or KYMR?

Do insiders and institutionals believe in BNTX or KYMR?

Which has stronger valuation and earnings, BNTX or KYMR?

Which has more volatility & risk, BNTX or KYMR?

Summary

How does Kymera Therapeutics compare to Roivant Sciences?

Does the media refer more to KYMR or ROIV?

Do institutionals & insiders believe in KYMR or ROIV?

Which has more risk & volatility, KYMR or ROIV?

Do analysts rate KYMR or ROIV?

Is KYMR or ROIV more profitable?

Which has preferable earnings & valuation, KYMR or ROIV?

Summary

How does Kymera Therapeutics compare to Insmed?

Is INSM or KYMR more profitable?

Which has stronger earnings & valuation, INSM or KYMR?

Which has more volatility & risk, INSM or KYMR?

Do analysts rate INSM or KYMR?

Does the media prefer INSM or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools